Wordt geladen...
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
Insulin analog patent expiry is likely to mean that, increasingly, copies of original biopharmaceutical products will be submitted for authorization. Experience with biosimilars in other therapeutic areas suggests that careful regulation and caution are needed. Published guidelines of regulatory aut...
Bewaard in:
| Gepubliceerd in: | Diabetes Technol Ther |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Mary Ann Liebert, Inc.
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4504437/ https://ncbi.nlm.nih.gov/pubmed/25789689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2014.0362 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|